You can buy or sell INSY and other stocks, options, ETFs, and crypto commission-free!
INSYS Therapeutics, Inc. operates as a pharmaceutical company, which develops and commercializes supportive care products. It focuses on utilizing commercial pharmaceutical products that include Subsys, a proprietary sublingual fentanyl spray for BTCP in opioid-tolerant adult patients; and Syndros, a proprietary orally administered liquid formulation of dronabinol for the treatment of CINV and anorexia associated with weight loss in patients with AIDS. Read More The company was founded by John N. Kapoor on June 15, 1990 and is headquartered in Chandler, AZ.
52 Week High
52 Week Low
Seeking AlphaMay 16
Why Insys Therapeutics Is Unlikely To Survive
It has not been a pleasant week for Insys Therapeutics (INSY), as it has announced poor first-quarter 2019 results, along with a news release providing a liquidity update in which it is stated that there is substantial doubt about the company's ability to continue as a going concern.
Wall Street JournalMay 13
Opioid Trouble Weighs on Insys as Short Sellers Cash In
Short sellers are cashing in as the country’s opioid crisis begins claiming corporate casualties. Insys Therapeutics Inc. said Friday it could be headed to bankruptcy, short on cash and overloaded with legal costs from opioid addiction lawsuits and the racketeering convictions of co-founder John Kapoor and other former company executives. The......
-$0.21 per share
-$0.55 per share